CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update
March 19 2017 - 6:00PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced that members of the management
team will host a teleconference on Monday, March 20, 2017, at 8:00
a.m. ET to provide a corporate update.
Conference Call/Webcast Information Interested
parties may access the live audio webcast of the teleconference
through the Investor and News page of CytomX's website at
http://ir.cytomx.com or by dialing 877-809-6037 and using the
passcode 90993451. A replay will be available on the CytomX
website or by dialing 855-859-2056 and using the passcode
90993451. The replay will be available from March 20, 2017,
at 11:00 a.m. ET until March 27, 2017, at 11:00 a.m. ET.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. The company utilizes the
platform to create proprietary cancer immunotherapies against
clinically-validated targets, such as PD-L1, and first-in-class
cancer therapeutics against novel targets, such as CD166, that are
difficult to drug without causing damage to healthy tissues.
Probody therapeutics are designed to take advantage of unique
conditions in the tumor microenvironment to enhance the
tumor-targeting features of an antibody and reduce drug activity in
healthy tissues. The company’s lead program, CX-072, a
wholly-owned PD-L1-targeting Probody therapeutic, is being
evaluated in a Phase 1/2 study. The Investigational New Drug filing
for CX-2009 is planned for the first half of 2017. CX-2009 is
a first-in-class Probody drug conjugate targeting the highly
expressed tumor antigen, CD166. CX-072 is part of PROCLAIM
(Probody Clinical Assessment In Man), an international umbrella
clinical trial program that provides clinical trial sites with
access to the company’s novel therapies under one central
protocol. In addition to its proprietary programs, CytomX is
collaborating with strategic partners including AbbVie,
Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. For more information, visit
www.cytomx.com or follow us on Twitter.
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements. Our Probody
platform is beginning clinical development, and the process by
which clinical development could potentially lead to an approved
product is long and subject to significant risks and uncertainties.
Projected net cash utilization and capital resources are subject to
substantial risk of variance based on a wide variety of factors
that can be difficult to predict. Applicable risks and
uncertainties include those relating to our preclinical research
and development, clinical development, and other risks identified
under the heading "Risk Factors" included in our filings with the
SEC. The forward-looking statements contained in this press release
are based on information currently available to CytomX and speak
only as of the date on which they are made. CytomX does not
undertake and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Media Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2024 to May 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From May 2023 to May 2024